在水系统中追踪药品:关注神经退行性和精神病治疗
Paula Paíga1, Cristina Delerue-Matos1
1REQUIMTE/LAQV, Instituto Superior de Engenharia do Porto, Instituto Politécnico do Porto, Rua Dr. António Bernardino de Almeida, 431, 4249-015 Porto, Portugal.
Journal of xenobiotics
|November 25, 2024
概括
像精神病药物和阿尔茨海默/帕金森病药物等药品存在于水中. 这项研究开发了一种检测这些残留物的方法,发现了21种化合物,其中咖啡因是最丰富的.
科学领域:
- 环境化学环境化学
- 分析化学 分析化学
- 环境科学 环境科学
背景情况:
- 水生环境中的制药残留物对生态系统和人类健康构成风险.
- 准确检测和量化这些化合物对于风险评估至关重要.
- 阿尔茨海默病 (AD),帕金森病 (PD) 和精神病药物是常用的,可能进入水体.
研究的目的:
- 开发和验证一种强大的分析方法来检测30种药物化合物,包括用于AD,PD,精神疾病和咖啡因的药物.
- 应用开发的方法来分析地表和废水样本.
- 评估水生生态系统中这些制药残留物的流行程度和度.
主要方法:
- 优化液体染色学和质谱学参数,以进行敏感检测.
- 应用验证的方法来分析25个表面和废水样本.
- 检测到的药物化合物及其代谢物的量化.
主要成果:
- 在分析的水样中检测到30种向药物化合物中的21种.
- 在所有样本中检测到素;咖啡因是最丰富的化合物,度高达76,991 ng/L.
- 检测到的度各不相同:咖啡因 (29.876,991 ng/L),精神药物 (
结论:
- 开发的分析方法有效地检测和量化水生环境中的各种药物残留物.
- 药品的广泛存在,包括精神病和AD/PD药物,突显了环境监测的必要性.
- 高度的咖啡因表明人类大量消费,并有可能广泛分布在环境中.
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K


